HCM
PCRX icon

Hoplite Capital Management’s Pacira BioSciences PCRX Stock Holding History

Hoplite Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-605,720
Closed -$20.4M – 38
2016
Q2 		$20.4M Sell
605,720
-398,113
-40% -$19.6M 1.01% 27
2016
Q1 		$53.2M Sell
1,003,833
-223,072
-18% -$13M 2.68% 15
2015
Q4 		$94.2M Sell
1,226,905
-194,608
-14% -$11M 4.09% 10
2015
Q3 		$58.4M Buy
1,421,513
+159,154
+13% +$9.75M 2.21% 21
2015
Q2 		$89.3M Buy
+1,262,359
New +$99.4M 2.39% 17

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hoplite Capital Management's PCRX Position: Q3 2016 in Review

Hoplite Capital Management sold out of Pacira BioSciences (PCRX) in Q3 2016, closing a stake of 605,720 shares — an estimated $20.4M sold.

Hoplite Capital Management first reported a position in PCRX in Q2 2015 and held it in 5 quarters. The position peaked at $94.2M in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2016.

  • Hoplite Capital Management reported no remaining Pacira BioSciences position as of Q3 2016 after selling out during the quarter.
  • Hoplite Capital Management sold 605,720 Pacira BioSciences shares in Q3 2016, an estimated $20.4M.
  • Hoplite Capital Management first reported a position in Pacira BioSciences in Q2 2015 and held it in 5 quarters.
  • Hoplite Capital Management's Pacira BioSciences position peaked at $94.2M in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2016.

Based on Hoplite Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.